Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,711 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Multiple Sclerosis, Magnetic Resonance Imaging, Biomarkers, Clinically Isolated Syndrome, Radiologically Isolated Syndrome
Interventions
Brain MRI
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years
Enrollment
300 participants
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Multiple Sclerosis
Interventions
Wellness Patient Message
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 89 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Multiple Sclerosis
Interventions
peginterferon beta-1a, Rebif
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced May 21, 2026, 5:55 PM EDT
Terminated Phase 2 Interventional Results available
Conditions
Autoimmune Encephalitis
Interventions
Ocrelizumab, Saline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced May 21, 2026, 5:55 PM EDT
Completed Phase 3 Interventional Results available
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
GA 20 mg/mL, GA 40 mg/mL
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Cullman, Alabama • Gilbert, Arizona • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Multiple Sclerosis
Interventions
balance based torso weighting
Other
Lead sponsor
University of St. Augustine for Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Augustine, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced May 21, 2026, 5:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Immune Globulin Subcutaneous (Human)
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
PIPE-307 Dose A, PIPE-307 Dose B, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Berkeley, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
Autologous mesenchymal stem cell transplantation
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Multiple Sclerosis
Interventions
Speed of Processing Training (SPT), Placebo Control
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 59 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Multiple Sclerosis
Interventions
CBT for Uncertainty Tolerance, Traditional CBT
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Neurogenic Detrusor Overactivity
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Orange, California • Jacksonville, Florida • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced May 21, 2026, 5:55 PM EDT
Terminated Phase 4 Interventional Results available
Conditions
Multiple Sclerosis
Interventions
Natalizumab 300 MG in 15 ML Injection
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Betaferon/Betaseron
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
51
States / cities
Tucson, Arizona • Berkeley, California • Irvine, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
Interventions
CNP-106, Placebo
Drug · Other
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Phoenix, Arizona • Brea, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Multiple Sclerosis
Interventions
single-use autoinjector with a prefilled liquid Avonex syringe, Avonex prefilled syringe via manual IM injection, BG9418 (interferon beta-1a)
Device · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Maitland, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced May 21, 2026, 5:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Teriflunomide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases
Interventions
Stem Cell Transplantation, CD34 selection
Procedure · Device
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Myasthaenia Gravis
Interventions
Decartes-08, Placebo Drug
Biological · Other
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Tucson, Arizona • Carlsbad, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Multiple Sclerosis
Interventions
Mycophenolate Mofetil (cellcept)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced May 21, 2026, 5:55 PM EDT
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced May 21, 2026, 5:55 PM EDT